February 13, 2017
MEMBER/CENTER HIGHLIGHTS
New Demonstration Grant Will Address Tobacco Disparities
Trapl
Erika Trapl
Erika Trapl, PhD, Case Comprehensive Cancer Center, Associate Director of the Prevention Research Center for Healthy Neighborhoods (PRCHN), and Associate Professor of Epidemiology & Biostatistics at the CWRU School of Medicine, received a one-year, $240,000 Tobacco Disparities Demonstration Project grant from the Ohio Department of Health (ODH) that will work to reduce rates of smoking in three targeted neighborhoods in Cleveland.

According to the PRCHN website, this grant will extend work in which the PRCHN is currently engaged as a partner of the Health Improvement Partnership-Cuyahoga (HIP-Cuyahoga) and Healthy Cleveland. Building on the Resident Team model developed by HIP-Cuyahoga, the Tobacco Disparities Project will utilize a multi-level approach to tobacco prevention and cessation by increasing adoption of 100% tobacco-free worksite policies and smoke-free home rules, as well as promoting free resources to assist smokers in quitting (e.g., Ohio QuitLine, smokefreeTXT, QuitGuide, and quitSTART). These strategies will be underpinned by a culturally informed media messaging campaign to raise awareness of dangers of tobacco, particularly cigar products, and encourage smoking cessation. more>
Study by Cleveland Clinic Researchers Explains how Brain Cancer Cells Avoid Immune System
Crain's Cleveland Business - Jan 26, 2017
Lathia, Justin
Justin Lathia
A study by Cleveland Clinic researchers helps explain how brain cancer cells avoid the immune system, offering potential pathways for new therapies.
The study uncovers some of the mystery behind how glioblastoma resists most cancer treatments, including chemotherapy, radiation and immunotherapy. The study, scheduled to be published in April in the medical journal Cell Stem Cell in April [ Alvarado, AG. Cell Stem Cell. 2016 Dec 27].

Glioblastoma is one of the most deadly and recurring brain cancers, according to a news release.

Justin Lathia, PhD, Case Comprehensive Cancer Center, a researcher in Cleveland Clinic's Lerner Research Institute, leads the team that found that glioblastoma stem cells lose a receptor that would otherwise let them sense they're in a damaged microenvironment, according to the release. If that's sensed, tumor cells would undergo cell death or bind to immune cells and be killed by the immune system. more>
Majhail Elected to Leadership Role of American Society for Blood Marrow Transplantation
Majhail, Navneet headshot
Navneet Majhail
Navneet Majhail, MD, MS, Case Comprehensive Cancer Center,  Director of the Cleveland Clinic Blood & Marrow Transplant Program, and Staff Physician with the Department of Hematology and Oncology at the Taussig Cancer Institute, has been  elected as Vice President for the American Society for Blood and Marrow Transplantation. Majhail will serve as President Elect in 2018, and as President of the society in 2019.
MARK YOUR CALENDARS
Cleveland Clinic Cancer Center Open House
All are welcome to attend the Cleveland Clinic Cancer Center open house on Saturday, Feb 18, from 1-4p at Cleveland Clinic's main campus. No registration is required. Event includes:
  • Self-guided tours of the new facility
  • Health screenings and wellness education
  • Children's activities
  • Healthy refreshments and giveaways
The cancer center is located at 10201 Carnegie Ave. (adjacent to the Crile Building, on the north side of Carnegie Avenue between East 102nd and East 105th Streets).

During the open house, complimentary parking will be available in the E. 100th Street Garage, located off Carnegie Avenue.
2017 St. Baldrick's "Shave It Off!"
2017 St. Baldrick's "Shave It Off!" event will be held Friday, March 10, 2017 from 6a-6p in the UH Rainbow Babies and Children's Hospital Performance Area. 

The St. Baldrick's Foundation head shaving event has become an annual Spring ritual.  On March 10, 2017, people will shave their heads in solidarity with children who have cancer and typically lose their hair during treatment, while raising critical funds for childhood cancer research!  

You can help by making a donate and helping to fundraise, signing-up to shave your head, and spreading the word about St. Baldrick's and this event. Visit the team page for more information. 

We thank St. Baldrick's for being a strong supporter of the pediatric cancer research being conducted at our institutions! 
1st Annual Cancer Disparities Symposium: Building Bridges to Address Cancer Disparities
March, 17, 2017 | Cleveland, OH
 
The Case Comprehensive Cancer Center is excited to announce the inaugural Cancer Disparities Symposium: Building Bridges to Address Cancer Disparities

Understanding and addressing cancer disparities is complex and multi-faceted, and requires attention across the translational spectrum. This event will showcase cutting-edge research, with a focus on reducing and eliminating disparities in cancer, going from bench-to-bedside-to-community and back. This important symposium will also feature two keynote addresses, including a key leader in our community, and an internationally-recognized cancer disparities researcher. We will promote the exchange of ideas and collaborative opportunities among scientists, clinicians, government, and community representatives. 

The day will begin at approximately 8a with several research presentations, panel discussions, and a keynote address from Lena Grafton, MPH, CHES, Community Engagement Coordinator for NEOMED-CSU Partnership for Urban Health at Cleveland State University. The program will culminate in a scientific keynote address from Kolawole Okuyemi, MD, MPH, Director of the  Cancer Health  Disparities Program at the University of Minnesota Masonic  Cancer Center, and Professor of Family Medicine and Community Health.  Dr. Okuyemi's presentation will conclude at 1p. Following this will be an optional mini-retreat, during which we hope you will participate to discuss objectives and future directions for the Case Comprehensive  Cancer Center Office of  Cancer  Disparities Research.
 
We are very excited about this event, and hope you will register to participate.  This event is free, but pre-registration is required
VELOSANO 2017
Join Our Team! 
Registration is now open for VeloSano Bike to Cure, July 21-23, 2017!  

The Case Comprehensive Cancer Center has been honored to participate in the VeloSano Bike to Cure for the past two years, and is planning for an even stronger team in 2017! We would love to double our team size this year.  Visit our team page to  register to ride with us! The Case CCC will waive registration fees for the first 40 registrants who join our team by March 1st .   Email Team Captain Caroline El Sanadi at  [email protected]  for the waiver code.

If you don't want to ride but still want to show your support, please consider being a virtual rider or volunteering with our cheer station. 

Remember, 100% of money raised through VeloSano goes to cancer research! 
CASE CCC IN THE NEWS
Crain's Cleveland Business - Feb 12, 2017
The new seven-story building added to the east end of Cleveland Clinic's main campus consolidates cancer services into one space, in an effort to add convenience for patients, coordination for providers and, ultimately, better care.  The approximately $276 million Cleveland Clinic Taussig Cancer Center, which will begin seeing patients March 6, is located on the north side of Carnegie Avenue between East 102nd and 105th streets.  It fits with the system's patient-centered culture and focus on multi-disciplinary care, said Dr. Brian J. Bolwell, chairman of the Clinic's Taussig Cancer Institute and Associate Director for the Taussig Cancer Institute, Case Comprehensive Cancer Center, who has been in his role for six years.  "One of the first things that I did and that we did as a group was to step back and say, 'What do we want cancer to be at the Cleveland Clinic?' " Bolwell said. "And it was pretty evident that we had opportunities to make the cancer programs more of their own organizational units."  That idea is evident in the new building, which is organized into "pods," each dedicated to a cancer type. For instance, all breast cancer patients would go to the same space, where doctors will come to them - instead of the patients having to stop by multiple offices - and where the nurses will become experts in that disease type.
Helio/HemOnc Today - Feb 8, 2017
Clinical trials routinely use strict enrollment criteria that exclude patients who are most likely to benefit from the treatment under investigation, according to study results published in LeukemiaTrials are not being designed to include participants who are representative of society,  Mikkael A. Sekeres, MD, MS,  Deputy Associate Director for Clinical Research and Director, Clinical Trials, Case Comprehensive Cancer Center, and Director of the leukemia program in the department of hematologic oncology and blood disorders at Cleveland Clinic Taussig Cancer Institute, and colleagues concluded...Abby Statler, MPH, MA, research regulatory quality assurance coordinator at Taussig Cancer Institute, served as lead author and initiated this study. In reviewing studies, she observed many similarities in the eligibility criteria of cancer trials
FUNDING OPPORTUNITIES
Limited Submission: V Foundation for Cancer Research 2017 Translational Research Award
Deadline: Feb 24, 2017
The Case Comprehensive Cancer Center is invited to submit TWO nominees for consideration for the V Foundation Translational Award, if at least one of the two nominee applicants is submitting a research project that focuses on the biological basis of cancer disparities experienced by patients from minority ethnic or racial populations in cancer causes, aggressiveness, treatment or relapse. Minorities for the purposes of this application are defined as African Americans or people of African descent, Pacific Islanders, Hispanic Americans and Native Americans and Alaskan Natives. 

As in previous years, any area of cancer research is permitted. However, research on cancers that are more prevalent or aggressive in specific ethnic populations is encouraged, but not required. Cancers in which ethnic and racial disparities have previously been shown include: lung and bronchus, colon and rectum, breast, prostate, uterine, cervix, stomach and liver. As in 2016, among the highly ranked finalists for the 2017 Translational Award program, the V Foundation will designate at least one of the highest ranked applications as the recipient of a Stuart Scott Memorial Fund Translational Research Award. While not required, the Foundations has a special interest in supporting immune oncology and immunotherapy research, when applicable.

To be considered for the nomination, submit a one-page LOI and biosketch to Kristin Waite ([email protected]) by Friday, February 24, 2017. 
Limited Submission:  Pilot Projects in Non-AIDS Defining Cancers
DEADLINES: February 27, 2017
With support from a supplement to its NCI P30 grant, the Case Comprehensive Cancer Center in coordination with the CWRU/UH Center for AIDS Research (CFAR) is
providing seed funding for the development of cancer research projects  focusing on the interface between aging and HIV infection in Non-AIDS Defining Cancers (NADC). The goal of this RFA is to build collaborative projects in cancer biology, aging, immunology, HIV/AIDS, systems biology/informatics, geriatric oncology, geriatric epidemiology, and/or cancer survivorship that will be competitive for nationally-funded multi-PI awards.

AWARD DESCRIPTION:
  • Funding for research teams with a focus on unique aspects of aging and NADC in HIV positive patients
  • FOUR research projects will be awarded over two rounds of funding (this is the second round)
  • Each research project will be funded at a level up to $50,000 for one year 
When Everyone Survives Leukemia Research Foundation
Deadline: Mar 1, 2017
This request for proposals (RFP) is offered by the  When Everyone Survives Foundation (WES Foundation)  to solicit innovative research in leukemia. Grants of $50,000 for one year are offered to new and established investigators who are requesting support for laboratory, translational, or clinical research related to acute leukemia. The WES Foundation is supporting leukemia research because it recognizes that significant advances in the understanding, diagnosis, and treatment of leukemia are needed to achieve the goal of "when everyone survives". Renewal of initial research support may be considered for one or more additional years based upon productivity.
SWOG/Hope Foundation Impact Award
Deadline: Mar 1, 2017
Request for Applications: Opportunities for Pilot Projects from VeloSano Bike to Cure
Deadline: Mar 6, 2017
With the generous support from VeloSano Bike to Cure 2016, the Case Comprehensive Cancer Center is providing seed funding for the initiation of novel projects aligned with at least one of the seven Research Programs (GI Cancer Genetics, Molecular Oncology, GU Malignancies, Hematopoietic and Immune Cancer Biology, Developmental Therapeutics, Cancer Imaging, or Cancer Prevention, Control, & Population Research) or the Brain Tumor or Breast Cancer research initiatives within the Center. Highly innovative and impactful proposals are sought that will generate key data for larger, nationally competitive grants that interface with the Strategic Plan of the aligned program(s). Proposals must include collaborative, multi-investigator projects.  In addition, projects that focus on renal cancer biology, disparities research, brain tumors, or drug discovery and screening are particularly encouraged.

Eligibility for funds will be restricted to lead PIs that are Center members who participated in VeloSano Bike to Cure 2016 (rider, virtual rider, or volunteer). In addition, the lead PI of the application must not be eligible for CCF VeloSano funding. Co-PIs and Co-investigators are not required to have been VeloSano participants. All awardees (PIs and co-investigators) will be expected to participate in VeloSano 2017 as well as to present their research progress when requested by the Case Comprehensive Cancer Center.
UH Harrington Scholar-Innovator Program
LOI Deadline: Apr 5, 2017
Invited Application Deadline: May 31, 2017
The Harrington Scholar-Innovator Award recognizes physician-scientist innovators throughout the U.S. whose research has the potential to change standard of care. The Scholar-Innovator Award provides research and drug development support to help bridge the gap between basic discovery and the clinic.

Up to 12 Harrington Scholar-Innovator awards will be made each year through a competitive selection process. Awardees are selected by the Harrington Discovery Institute's  Scientific Advisory Board.
Dr. Alma S. Adams Scholarship for Outreach and Health Communications to Reduce Tobacco Use Among Priority Populations
Deadline: Apr 30, 2017
Putting an end to tobacco use depends on young people who are eager to help achieve a tobacco-free generation. That's why Truth InitiativeĀ® is offering two $5,000 scholarships to support undergraduate and graduate students who are innovatively confronting tobacco use.

Over the past decade, the Dr. Alma S. Adams Scholarship for Outreach and Health Communications to Reduce Tobacco Use Among Priority Populations has recognized students for their commitment to community service and use of the creative arts to raise awareness of tobacco's harmful impacts in  disproportionately affected communities.

Alex's Lemonade Stand Foundation Pediatric Oncology Student Training Program
Deadline: May 1, 2017
Alex's Lemonade Stand Foundation (ALSF) is dedicated to funding pediatric oncology researchers at critical points in their careers.  The Pediatric Oncology Student Training (POST) Program is designed for undergraduate, graduate and medical students who have an interest in pediatric oncology research and would like to experience the field first hand by working on a mentored research project during a school break (typically summer).  Students train with a pediatric oncology research mentor who is an ALSF grantee, Advisory Board member, or Review Board member.  Students may join a research project underway in a mentor's lab or begin an original investigation with the mentor.

NIH BULLETIN- Notices and Funding Opportunities
Deadline: Feb 15, 2017; Jun 15, 2017; Feb 15, 2018; Jun 15 2018; Feb 15, 2019; Jun 14, 2019




Notice of a Pre-Application Technical Assistance Webinar for PA-17-143 "NCI Activities to Promote Technology Research Collaborations (APTRC)"(NOT-CA-17-028)

Multilevel Interventions in Cancer Care Delivery: Building From the Problem of Follow-up to Abnormal Screening Tests (U01)(PAR-17-146)
Deadline: May 26, 2017; Sep 21, 2017 (LOI due 30 days prior)

Activities to Promote Technology Research Collaborations (APTRC) for Cancer Research (Admin Supp)(PA-17-143)
Deadline: Apr 12, 2017; Jul 25, 2017; and Dec 12, 2017

Basic Cancer Research in Cancer Health Disparities (R01)(PAR-15-093)
Deadline: Jun 19, 2017; Nov 17, 2017
EVENTS
Tues, Feb 14
Diversity Town Hall Meeting
8a WRB 1-413

Cancer Center Research in Progress Seminar
Alex Gooding
Student, Medical Scientist Training Program
Schiemann Lab, General Medical Sciences-Oncology, CWRU 
"BORG: Role for a Novel lncRNA in mediating Breast Cancer Metastasis and Escape from
Dormancy"
3p WRB 3-136
Wed, Feb 15
Best of San Antonio Breast Cancer Symposium
Embassy Suites, Independence, OH

Hem/Onc Grand Rounds
8a Lerner B-151

Department of Cellular and Molecular Medicine
Paul Erhardt, PhD
Center for Drug Design & Development, University of Toledo
"Its Evolution; Some Projects with Interesting Hurdles; and, How Might Something Like it Work for the LRI"
10a NE1-205
Thurs, Feb 16
Developmental Therapeutics Journal Club
9a R4-013

Cancer Center Trainee Seminar
Vinay Varadan, PhD
Assistant Professor, General Medical Sciences- Oncology; Scholar, CoGEC, CWRU SOM
"Signs of the unseen - Integrative tumor portraits to decode disease processes
AND
Golam Kibria, PhD
Postdoctoral Fellow, Pathology, Cancer Biology Training Grant, CWRU
"Development of Cancer stem cell targeted exosomes for the treatment of breast cancer metastasis"
12p WRB 3-136 

Neurosciences Seminar
Stephen J. Lewis, PhD
Professor, Pediatrics - Pulmonology, Allergy and Immunology, CWRU
"S-nitrosothiols as neurotransmitters in the CNS"
12:10p BRB 105

Molecular Biology & Microbiology
Susan Brady-Kalnay, PhD
Professor, Molecular Biology & Microbiology, CWRU
"Receptor Protein Tyrosine Phosphatase Cleavage: A New Paradigm for Cancer Detection and Imaging of the Tumor Microenvironment"
1p SOM W203

Stem Cell Biology and Regenerative Medicine Seminar
Alysson Muotri, PhD
Associate Professor, Director of Stem Cell Program, Dept of Pediatrics & Cellular and Molecular Medicine, University of California, San Diego
"The impact of L1 retrotransposition and genetic mosaicism in the brain"
1p NE1-205
Fri, Feb 17
Hem/Onc Fellows
8a Breen Conf Rm 

Taussig Cancer Institute Grand Rounds
David Neil Hayes, MD
University of North Carolina
"Genomic Classification of Tumors of the Upper  Aerodigestive Track" 
8a R3/002-003

Cancer Center Seminar Series
Cameron Turtle, MBBS, PhD, FRACP, FRCPA
Associate Member, Fred Hutchinson Cancer Research Center
"CD19 CAR-T cell immunotherapy for adult B cell malignancies"
12p BRB 105

Immunology Invited Speaker Seminar Series
Charles E. Samuel, PhD
University of California, Santa Barbara
"Roles of RNA Editing by ADAR1 Adenosine Deaminase In Innate Immunity RNA Sensing"
12p NC1-202 
Mon, Feb 20
Case CCC DNA Damage and Repair
George Stark, PhD
Professor and Staff, Cancer Biology, CWRU/Cleveland Clinic
12p Wearn 137

Cancer Center Chalk Talk
Richard Lee, MD
Professor, Medicine, CWRU SOM 
Medical Director, Integrative and Supportive Oncology Program, UH Seidman Cancer Center
1p WRB 3-136
Tues, Feb 21
Cancer Center Research In Progress Seminar
3p WRB 3-136
Wed, Feb 22
Hem/Onc Grand Rounds
8a Lerner B-151
Thurs, Feb 23
Developmental Therapeutics Journal Club
9a R4-013

Molecular Biology and Microbiology Seminar
Michal Bonar
Tilton lab, Molecular Biology and Microbiology, CWRU
"Rapid and sensitive flow-based quantification, characterization and recovery of infectious virus"
AND
Zach Troyer
Tilton lab, Molecular Biology and Microbiology, CWRU
"Modulating Immune Responses with Protein Delivery via Lentiviral Vectors"
1p SOM W203
Fri, Feb 24
Hem/Onc Fellows 
8a Breen Conf Rm/Wearn 137

Taussig Cancer Institute Grand Rounds
8a R3/002-003

Cancer Center Seminar Series
Raymond DuBois, MD, PhD
Dean, College of Medicine
Medical University of South Carolina
"Inflammation, Inflammatory Mediators and Cancer Progression"
12p BRB 105

ADDITIONAL UPCOMING SYMPOSIUMS & EVENTS

Best of San Antonio Breast Cancer Symposium
Feb 15, 2017
Embassy Suites, Independence, OH

2017 Multidisciplinary Head and Neck Cancer Update
Mar 10-11, 2017
Portofino Bay Resort at Universal Studios
Orlando, FL
1st Annual Cancer Disparities Symposium: Building Bridges to Address Cancer Disparities
Mar 17, 2017
Wolstein Research Bldg

NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Careā„¢
Mar 23-25, 2017

GvHD National Symposium
Oct 13, 2017
Grand Event Center, Columbus, OH
PREVIOUSLY ANNOUNCED OPPORTUNITIES


Deadline: Open

Deadline: Open

Case Comprehensive Cancer Center 
11100 Euclid Avenue, Wearn152
Cleveland, OH 44106-5065